Big Gain For Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI:NASDAQ) jumped higher at $6.07, a gain of 41.2%. On Mon, Mar 10, 2025, TRVI:NASDAQ hit a New 2-Week High of $6.07. The stock appeared on our News Catalysts scanner on Mon, Mar 10, 2025 at 02:11 PM in the 'BIOTECH' category. From Mon, Feb 24, 2025, the stock recorded 50.00% Up Days and 54.55% Green Days
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 176.92%
- Heidmar Maritime Holdings Corp. (HMR:NASDAQ), 69.54%
- Redfin Corporation (RDFN:NASDAQ), 67.87%
- Checkpoint Therapeutics, Inc. (CKPT:NASDAQ), 61.13%
- Sharps Technology Inc. (STSS:NASDAQ), 48.3%
- Protagonist Therapeutics, Inc. (PTGX:NASDAQ), 45.89%
- Bally's Corporation (BALY:NYSE), 42.74%
- Mineralys Therapeutics Inc. (MLYS:NASDAQ), 42.21%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 41.16%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 39.5%